Three-statement Excel model · 22 quarters and 5 fiscal years of history · 10 quarters and 5 fiscal years of projections
About the ABBV model
This three-statement Excel model covers AbbVie Inc. (ABBV): its income statement, balance sheet and cash flow statement. It holds 22 quarters and 5 fiscal years of history and 10 quarters and 5 fiscal years of projections.
Projected revenue is built from KPI drivers: YoY growth % x therapeutic area, with Skyrizi / Rinvoq / Humira broken out (8 buckets, exact to filed revenue), across 8 segments.
Beyond the income statement, the workbook has these sections: Adjusted (Non-GAAP) Reconciliation, KPI Drivers, Balance Sheet and Cash Flow Statement.
Model thesis: Amortisation roll-off, not operations, drives GAAP margin; adj EPS $13.96 FY26E on guide, 8% under Street by FY28E
On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated October 19, 2026.
Income statement preview
Columns FY2023–FY2025 are actual results and FY26E–FY28E are our estimates. Figures were recalculated in Excel on October 19, 2026. Dollars in millions, except per share data.
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| FY2023 | FY2024 | FY2025 | FY26E | FY27E | FY28E | |
| Skyrizi | 7,763.0 | 11,718.0 | 17,562.0 | 21,641.8 | 24,756.8 | 27,282.5 |
| Rinvoq | 3,969.0 | 5,971.0 | 8,304.0 | 10,202.9 | 11,772.2 | 13,090.2 |
| Humira | 14,404.0 | 8,993.0 | 4,540.0 | 2,991.4 | 2,427.8 | 2,136.5 |
| Immunology | $26,136.0 | $26,682.0 | $30,406.0 | $34,836.1 | $38,956.8 | $42,509.1 |
| Neuroscience | $7,717.0 | $8,999.0 | $10,767.0 | $12,803.7 | $14,368.0 | $15,804.8 |
| Oncology | 5,943.0 | 6,673.0 | 6,655.0 | 6,593.4 | 6,824.6 | 7,234.1 |
| Aesthetics | 5,294.0 | 5,176.0 | 4,860.0 | 4,971.8 | 5,071.2 | 5,223.4 |
| Other Key Products | 3,806.0 | 3,648.0 | 3,736.0 | 3,724.3 | 3,575.3 | 3,432.3 |
| Eye Care and All Other | 5,422.0 | 5,156.0 | 4,736.0 | 4,452.7 | 4,274.6 | 4,146.3 |
| Total Revenue | $54,318.0 | $56,334.0 | $61,160.0 | $67,381.9 | $73,070.5 | $78,350.1 |
| Less: Cost of Products Sold | ($20,415.0) | ($16,904.0) | ($18,204.0) | ($16,941.9) | ($16,731.8) | ($16,743.2) |
| Gross Profit | $33,903.0 | $39,430.0 | $42,956.0 | $50,440.0 | $56,338.8 | $61,606.8 |
| Less: Selling, General and Administrative | ($12,872.0) | ($14,752.0) | ($14,010.0) | ($14,556.2) | ($15,382.3) | ($16,337.3) |
| Less: Research and Development | (7,675.0) | (12,791.0) | (9,096.0) | (9,774.6) | (10,227.8) | (10,888.3) |
| Less: Acquired IPR&D and Milestones | (778.0) | (2,757.0) | (5,016.0) | (1,035.0) | (1,826.8) | (1,958.8) |
| Other Operating Income / (Expense), Net | 179.0 | 7.0 | 241.0 | 0.0 | 0.0 | 0.0 |
| Less: Total Operating Costs and Expenses | ($41,561.0) | ($47,197.0) | ($46,085.0) | ($42,307.7) | ($44,168.6) | ($45,927.5) |
| Operating Earnings | $12,757.0 | $9,137.0 | $15,075.0 | $25,074.3 | $28,901.9 | $32,422.5 |
| Depreciation and Amortization (from cash flow) | $8,698.0 | $8,386.0 | $8,139.0 | $7,240.7 | $6,363.8 | $5,799.1 |
| EBITDA | $21,455.0 | $17,523.0 | $23,214.0 | $32,314.9 | $35,265.8 | $38,221.7 |
| Less: Interest Expense, Net | ($1,684.0) | ($2,160.0) | ($2,627.0) | ($2,844.7) | ($2,677.7) | ($2,150.7) |
| Less: Net Foreign Exchange Loss | (146.0) | (21.0) | (58.0) | 0.0 | 0.0 | 0.0 |
| Less: Other Expense, Net | (4,677.0) | (3,240.0) | (5,793.0) | (6,612.2) | (5,480.3) | (5,876.3) |
| Earnings Before Income Tax Expense | $6,250.0 | $3,716.0 | $6,597.0 | $15,617.4 | $20,744.0 | $24,395.5 |
| Less: Income Tax Expense / (Benefit) | ($1,377.0) | $570.0 | ($2,364.0) | ($2,961.1) | ($3,941.4) | ($4,635.2) |
| Net Earnings | $4,873.0 | $4,286.0 | $4,233.0 | $12,656.3 | $16,802.6 | $19,760.4 |
| Less: Net Earnings Attributable to Noncontrolling Interest | (10.0) | (8.0) | (7.0) | (9.0) | (8.0) | (8.0) |
| Net Earnings Attributable to AbbVie Inc. | $4,863.0 | $4,278.0 | $4,226.0 | $12,647.3 | $16,794.6 | $19,752.4 |
| Ratios & Assumptions | ||||||
| Gross Margin | 62.4% | 70.0% | 70.2% | 74.9% | 77.1% | 78.6% |
| Incremental Gross Margin | 180.3% | 274.2% | 73.1% | 120.3% | 103.7% | 99.8% |
| Operating Margin | 23.5% | 16.2% | 24.6% | 37.2% | 39.6% | 41.4% |
| Net Margin | 9.0% | 7.6% | 6.9% | 18.8% | 23.0% | 25.2% |
The full workbook adds 22 historical and 10 projected quarters, plus Adjusted (Non-GAAP) Reconciliation · KPI Drivers · Balance Sheet · Cash Flow Statement — every subtotal a live formula, every projection traced to a driver.
AbbVie research
Aardvark Labs Capital Research has published 6 reports on AbbVie (ABBV). The latest is the Q3 2026 Earnings Recap, published November 1, 2026, rated Underperform.
Promises Kept, Price Paid in Advance: A Clean Beat-and-Raise Meets a Stock That Has Run Through Our Bull Case
Methodology
Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.